Pharmacogenomics Drug-Gene Response (PGx)
Pharmacogenomic (PGx) testing unlocks how individual genetic variations impact drug metabolism, efficacy, and adverse reaction risks. By sequencing cytochrome P450 enzymes and drug transporters, providers can replace trial-and-error prescribing with precision pharmacology—optimizing dosages and preventing dangerous drug-drug and drug-gene toxicities.
Check If You Qualify
Takes under 2 minutes • 100% Covered under Medicare Part B
Who Should Consider This Screening?
Healthcare providers recommend this diagnostic panel for individuals with the following personal or family health indicators:
Biomarkers & Genes Evaluated in this Panel
Processed using high-complexity Next-Generation Sequencing (NGS) in CLIA-certified and CAP-accredited partner laboratories.
| Gene Symbol / Name | Clinical Significance | Actionable Impact |
|---|---|---|
| CYP2D6Cytochrome P450 Family 2 Subfamily D Member 6 | Metabolizes ~25% of all common prescription drugs, including beta-blockers, antiarrhythmics, SSRIs, and opioids. | Identifies Poor, Intermediate, Normal, or Ultrarapid metabolizers to guide precise dosing and avoid toxicity or therapeutic failure. |
| CYP2C19Cytochrome P450 Family 2 Subfamily C Member 19 | Critical for activation of antiplatelet agents (clopidogrel/Plavix), proton pump inhibitors, and antidepressants. | Prevents post-stent cardiac complications by identifying clopidogrel resistance and guiding alternative antiplatelet therapies. |
| CYP2C9 & VKORC1Warfarin & Statin Sensitivity Enzymes | Regulates anticoagulant clearance (Coumadin) and statin-induced myopathy risk. | Guides initial therapeutic warfarin dosing windows to avoid dangerous hemorrhagic or clotting events. |
| SLCO1B1Solute Carrier Organic Anion Transporter Family 1B1 | Controls hepatic uptake of HMG-CoA reductase inhibitors (simvastatin, atorvastatin). | Eliminates severe muscle pain (myopathy/rhabdomyolysis) by selecting well-tolerated statin alternatives. |
Sample Report & Diagnostic Action Plan
Every patient receives an easy-to-understand diagnostic summary and a detailed clinical report tailored for their primary care doctor.
CYP2C19 Intermediate Metabolizer (*1/*2) and SLCO1B1 Decreased Function (*5 allele).
Consider alternative antiplatelet therapy to clopidogrel (e.g. ticagrelor/Prasugrel) and adjust simvastatin dosage to prevent statin-related myopathy.
Medicare Part B Coverage Guidelines
Understand how federal CMS medical necessity guidelines apply to this specific diagnostic screening:
Covered by Medicare Part B when ordered by an attending physician for patients on polypharmacy regimens, patients initiating high-risk therapies (e.g. clopidogrel, warfarin), or patients with documented therapeutic failure/adverse reactions.
Ready to Check Your Eligibility for Pharmacogenomics Drug-Gene Response (PGx)?
Takes under 2 minutes • Painless at-home cheek swab • 100% Physician Reviewed